Tag: visibility
GenSight Biologics wants to extend its visibility beyond April 2024 – 04/05/2024 at 10:31
(AOF) – GenSight Biologics (-5.89% to 0.39 euros) announces that its cash position stands at 2.2 million euros as of March 31, 2024, compared to 2.1 million euros as of…
GenSight: financial visibility guaranteed until the end of April – 04/05/2024 at 12:33
(CercleFinance.com) – GenSight Biologics fell on Friday on the Paris Stock Exchange, with analysts noting the continued lack of visibility over the company’s cash flow. As of March 31, its…
GenSight Biologics wants to extend its visibility beyond April 2024
(AOF) – GenSight Biologics (-5.89% to 0.39 euros) announces that its cash position stands at 2.2 million euros as of March 31, 2024, compared to 2.1 million euros as of…
Aelis Farma: cash flow of 20.2 million, visibility until the end of 2025 – 04/02/2024 at 6:16 p.m.
(AOF) – Aelis Farma announces cash flow of 20.2 million euros as of December 31, 2023, confirming its financial visibility until the end of 2025. The biotech specializing in the…
Aelis Farma: cash flow of 20.2 million, visibility until the end of 2025
(AOF) – Aelis Farma announces cash flow of 20.2 million euros as of December 31, 2023, confirming its financial visibility until the end of 2025. The biotech specializing in the…
Abivax: 261 million in cash, visibility until the end of 2025
(AOF) – Abivax (+1.19% to 13.56 euros) is up after the announcement of its results. The biotech announces a cash position of 261 million euros at the end of 2023,…
Transgene: 15.7 million in cash at the end of 2023, visibility until the 4th quarter of 2025 – 03/27/2024 at 6:28 p.m.
(AOF) – Transgene displays 15.7 million euros of available cash as of December 31, 2023, compared to 26.8 million euros at the end of 2022, which gives it financial visibility…
Transgene: 15.7 million in cash at the end of 2023, visibility until the 4th quarter of 2025
(AOF) – Transgene displays 15.7 million euros of available cash as of December 31, 2023, compared to 26.8 million euros at the end of 2022, which gives it financial visibility…
Correction: OPM: 10 million cash, visibility until early 2025
(AOF) – An error crept into the title of our dispatch this morning on OPM. The net loss figure has been corrected. Oncodesign precision medicine (OPM) announces cash flow of…
Correction: OPM: 10 million in cash, visibility until early 2025 – 03/27/2024 at 11:18
(AOF) – An error crept into the title of our dispatch this morning on OPM. The net loss figure has been corrected. Oncodesign precision medicine (OPM) announces cash flow of…
GenSight: the stock falls, financial visibility limited – 03/25/2024 at 10:41
(CercleFinance.com) – GenSight Biologics fell sharply on Monday on the Paris Stock Exchange after reporting annual results marked by a lack of financial visibility. The biopharmaceutical company, specializing in gene…
Sensorion: 37 million in cash, visibility until mid-2025
(AOF) – Sensorion has net available cash of 37 million euros, and says it is capable of meeting its cash flow needs beyond the next twelve months, i.e. until the…